opugotamig olatansine (IMGN-151) / AbbVie - LARVOL DELTA

GenSci140, a potential best-in-class FRα-directed biparatopic ADC, for the treatment of platinum-resistant ovarian cancer (AACR 2025) - "GenSci140 demonstrated superior in vivo anti-tumor efficacy compared to ELAHERETM and IMGN151 (competitor's next-generation FRα-directed biparatopic ADC product) across a variety of CDX models including ovarian cancer, NSCLC, and TNBC, irrespective of their FRα expression levels. These data suggest that GenSci140 could be a more effective and safer treatment option than the current standard of care for 2L PROC, potentially addressing the unmet need of patients with varying levels of FRα expression. Therapeutic potential of this molecule is currently further evaluated in IND-enabling studies."

Platinum resistant • Breast Cancer • Endometrial Cancer • Epithelial Ovarian Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Solid Tumor • Triple Negative Breast Cancer • FOLR1

IMGN151-1001: First in Human Study of IMGN151 in Recurrent Gynaecological Cancers (clinicaltrials.gov) - P1 | N=423 | Recruiting | Sponsor: AbbVie | Trial completion date: Dec 2025 ➔ Feb 2027 | Trial primary completion date: Dec 2024 ➔ Feb 2027

Trial completion date • Trial primary completion date • Cervical Cancer • Endometrial Cancer • Fallopian Tube Cancer • Gynecologic Cancers • High Grade Serous Ovarian Cancer • Oncology • Ovarian Cancer • Peritoneal Cancer • Solid Tumor • FOLR1

First in Human Study of IMGN151 in Recurrent Gynaecological Cancers (clinicaltrials.gov) - P1 | N=423 | Recruiting | Sponsor: ImmunoGen, Inc. | N=227 ➔ 423

Enrollment change • Cervical Cancer • Endometrial Cancer • Fallopian Tube Cancer • Gynecologic Cancers • High Grade Serous Ovarian Cancer • Oncology • Ovarian Cancer • Peritoneal Cancer • Solid Tumor • FOLR1

IMGN151: Protection of composition-of-matter patent until 2040 (Immunogen) - Corporate Presentation

Patent • Oncology

First in Human Study of IMGN151 in Recurrent Endometrial Cancer and Recurrent, High-grade Serous Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers (clinicaltrials.gov) - P1 | N=227 | Recruiting | Sponsor: ImmunoGen, Inc. | Trial primary completion date: Jun 2024 ➔ Dec 2024

Trial primary completion date • Endometrial Cancer • Fallopian Tube Cancer • Oncology • Ovarian Cancer • Ovarian Serous Adenocarcinoma • Peritoneal Cancer • Solid Tumor • FOLR1

AbbVie Completes Acquisition of ImmunoGen (PRNewswire) - "AbbVie...announced today that it has completed its acquisition of ImmunoGen...With the completion of the acquisition, ImmunoGen is now part of AbbVie...ELAHERE (mirvetuximab soravtansine-gynx) is the first and only antibody-drug conjugate (ADC) approved by the U.S. Food and Drug Administration (FDA) in ovarian cancer...ImmunoGen's investigational Phase 1 asset, IMGN-151, is a next-generation FRα ADC for ovarian cancer with the potential for expansion into other solid tumor indications...Pivekimab sunirine, currently in Phase 2, is an investigational anti-CD123 ADC targeting blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare blood cancer, which was granted FDA breakthrough therapy designation for the treatment of relapsed/refractory BPDCN....AbbVie has acquired all outstanding ImmunoGen common stock for $31.26 per share."

M&A • Gynecologic Cancers • Hematological Malignancies • Oncology • Ovarian Cancer • Solid Tumor

First in Human Study of IMGN151 in Recurrent Endometrial Cancer and Recurrent, High-grade Serous Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers (clinicaltrials.gov) - P1 | N=227 | Recruiting | Sponsor: ImmunoGen, Inc. | Trial primary completion date: Sep 2023 ➔ Jun 2024

Trial primary completion date • Endometrial Cancer • Fallopian Tube Cancer • Oncology • Ovarian Cancer • Ovarian Serous Adenocarcinoma • Peritoneal Cancer • Solid Tumor

"$IMGN Olga Ab outlines development of IMGN151, son of Elahere. Hard not to see this as a summary of Elahere's shortcomings #ADC23" (@JacobPlieth)

[VIRTUAL] IMGN151 - A next generation folate receptor alpha targeting antibody drug conjugate active against tumors with low, medium and high receptor expression (AACR-II 2020) - "IMGN853 (i.e., mirvetuximab soravtansine and M9346A-sulfo-SPDB-DM4), a FRα targeting ADC, is currently in phase III (MIRASOL) clinical evaluation as monotherapy in patients with platinum-resistant epithelial ovarian cancer with high levels of FRα expression. In vivo IMGN151 induced complete tumor regressions of human tumor xenograft models with high (KB, H-score of 300), medium (Igrov-1 and Ishikawa, H-score of 140 and 100, respectively) and low (Ov-90, H-score of 30) FRα expression. All tested doses were well tolerated with no body weight loss observed.With a novel biparatopic antibody and linker payload design, IMGN151 has shown potent antitumor activity against ovarian cancer models with a broad range of FRα expression, which warrants further development into the clinic for patients with tumors expressing FRα at a wide range of levels."

Gynecologic Cancers • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Solid Tumor • Thoracic Cancer • Triple Negative Breast Cancer • FOLR1

"IMGN151, or $IMGN's quest for a better (less toxic?) Elahere #JPM23 $STRO" (@JacobPlieth)

First in Human Study of IMGN151 in Recurrent Endometrial Cancer and Recurrent, High-grade Serous Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers (clinicaltrials.gov) - P1 | N=227 | Recruiting | Sponsor: ImmunoGen, Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • Endometrial Cancer • Fallopian Tube Cancer • Oncology • Ovarian Cancer • Ovarian Serous Adenocarcinoma • Peritoneal Cancer • Solid Tumor

First in Human Study of IMGN151 in Recurrent Endometrial Cancer and Recurrent, High-grade Serous Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers (clinicaltrials.gov) - P1 | N=227 | Not yet recruiting | Sponsor: ImmunoGen, Inc.

New P1 trial • Endometrial Cancer • Fallopian Tube Cancer • Oncology • Ovarian Cancer • Ovarian Serous Adenocarcinoma • Peritoneal Cancer • Solid Tumor

ImmunoGen Reports Recent Progress and 2021 Financial Results (Businesswire) - "Initiate GLORIOSA, a randomized Phase 3 trial of mirvetuximab in combination with bevacizumab maintenance in FRα-high platinum-sensitive ovarian cancer, in the second quarter of 2022; Initiate Trial 0420, a single-arm Phase 2 trial of mirvetuximab in combination with carboplatin followed by mirvetuximab continuation in FRα-low, medium, and high patients with platinum-sensitive ovarian cancer, in the second quarter of 2022; Begin enrollment in the Phase 1 study of IMGN151 following submission of chemistry, manufacturing, and controls (CMC) information to the FDA."

Enrollment status • New P2 trial • New P3 trial • Gynecologic Cancers • Oncology • Ovarian Cancer

ImmunoGen Reports Recent Progress and Third Quarter 2021 Financial Results (Businesswire) - "ANTICIPATED UPCOMING EVENTS: Release top-line data from the pivotal SORAYA study this quarter, with the goal of submitting the biologics license application (BLA) in the first quarter of 2022 to support potential accelerated approval in 2022. Present initial AML combination data for IMGN632 at the 2021 American Society of Hematology (ASH) Annual Meeting in December. Submit the IND application for IMGN151 by the end of 2021. Complete dose-escalation in the Phase 1 study evaluating IMGC936, with initial data anticipated in 2022. Generate top-line data for the confirmatory MIRASOL study in the third quarter of 2022."

BLA • Clinical data • IND • Acute Myelogenous Leukemia • Gynecologic Cancers • Hematological Malignancies • Oncology • Ovarian Cancer

[VIRTUAL] Next-generation ADCs (IMGN151 & IMGC936) (ADC-USA 2021) - "Innovated next-generation ADCs IMGN151 is a next generation FRα-targeting ADC engineered to include multiple technological innovations to maximize the potential clinical benefit for patients with a broad range of target expression IMGC936 is an investigational ADAM9-targeting ADC, comprised of a high-affinity humanized monoclonal antibody site-specifically coupled to DM21"

ADAM9 • FOLR1

ImmunoGen Reports Recent Progress and Second Quarter 2021 Financial Results (Businesswire) - "ANTICIPATED UPCOMING EVENTS: Submit the IND application for IMGN151 by the end of 2021."

IND • Oncology

[VIRTUAL] Targeting Folate Receptor Alpha (FRα) with IMGN151, a Next-Generation Antibody-Drug Conjugate (PEGS 2021) - "Mirvetuximab soravtansine, our first generation FRa-targeting ADC is in two phase III studies, MIRASOL and SORAYA, in patients with platinum-resistant epithelial ovarian cancer with high levels of FRa. To address the unmet need of additional patient populations, we developed a next-generation anti-FRa ADC, IMGN151, which is active against tumors with a broader range of FRa expression. IMGN151’s innovative design, including the biparatopic antibody, and favorable preclinical activity will be presented."

Oncology • Ovarian Cancer • Solid Tumor • FOLR1

ImmunoGen Reports Recent Progress and 2020 Financial Results (Businesswire) - “Support initiation of two investigator-sponsored trials of mirvetuximab plus carboplatin, including a randomized Phase 2 study in recurrent platinum-sensitive ovarian cancer and a neo-adjuvant study. Enroll patients in the pivotal cohort of the 801 Phase 1/2 study of IMGN632 in frontline BPDCN patients and generate top-line data in 12 to 18 months. Advance the 802 Phase 1b/2 study of IMGN632 in combination with azacitidine and venetoclax in R/R and frontline AML patients and as a monotherapy in minimal residual disease positive (MRD+) AML following frontline induction therapy. Present updated R/R BPDCN and initial AML combination data for IMGN632 at ASH 2021. Complete dose escalation and move to expansion cohorts in the Phase 1 study evaluating IMGC936, with initial data anticipated by the end of 2021 or early 2022. Submit the investigational new drug (IND) application for IMGN151 by the end of 2021.”

Enrollment status • IND • P1 data • Trial status • Acute Myelogenous Leukemia • Gynecologic Cancers • Hematological Malignancies • Oncology • Ovarian Cancer

ImmunoGen Presents Preclinical Data on IMGN151 at Virtual AACR Annual Meeting (Businesswire) - "ImmunoGen, Inc....announced preclinical data for its next generation anti-folate receptor alpha (FRα) ADC, IMGN151, which is being investigated in tumors with a broad range of FRα expression....The protease-cleavable linker deployed in IMGN151 improves stability and ADC exposure; as compared to IMGN853, pharmacokinetic studies in cynomolgus monkeys showed increased ADC half-life by 60 hours and conjugate exposure in vivo by 40%."

Preclinical • Oncology • Ovarian Cancer • Solid Tumor

ImmunoGen to present preclinical data on IMGN151 at AACR Virtual Annual Meeting (Businesswire) - "ImmunoGen...announced preclinical data for its next generation anti-folate receptor alpha (FRα) ADC, IMGN151, which is being investigated in tumors with a broad range of FRα expression. The data will be shared via poster presentation at the virtual American Association for Cancer Research (AACR) Annual Meeting II being held June 22-24, 2020...In tumor cells with medium and high FRα expression, IMGN151 boosted antibody binding events and payload delivery by 100% and 170%, respectively."

Preclinical • Breast Cancer • Cervical Cancer • Endometrial Cancer • Oncology • Ovarian Cancer

ImmunoGen reports recent progress and first quarter 2020 financial results (Businesswire) - “ANTICIPATED UPCOMING EVENTS: Present updated data from the FORWARD II platinum-sensitive triplet cohort evaluating mirvetuximab in combination with carboplatin and bevacizumab in the fall; Continue enrollment in IMGN632 monotherapy and combination cohorts; File IND for IMGC936 at the end of Q2; Transition IMGN151 into pre-clinical development.”

Enrollment status • IND • P2 data • Preclinical • Gynecologic Cancers • Oncology • Ovarian Cancer • Solid Tumor

ImmunoGen reports recent progress and first quarter 2020 financial results (Businesswire) - “ANTICIPATED UPCOMING EVENTS: Continue patient enrollment in pivotal SORAYA and confirmatory MIRASOL trials; Support initiation of an additional platinum-sensitive investigator sponsored trial evaluating mirvetuximab in combination with carboplatin in over 100 patients; Present initial data from the FORWARD II platinum-agnostic doublet cohort evaluating mirvetuximab in combination with bevacizumab in an oral presentation at the virtual American Society of Clinical Oncology (ASCO) Annual Meeting in May; Present pre-clinical data evaluating our next generation anti-folate receptor alpha (FRα) ADC, IMGN151, in ovarian cancer and other tumor types in a poster at the virtual American Association for Cancer Research (AACR) Annual Meeting in June.”

Enrollment status • P2 data • Preclinical • Trial status • Gynecologic Cancers • Oncology • Ovarian Cancer • Solid Tumor

ImmunoGen reports recent progress and 2019 financial results (Businesswire) - "ANTICIPATED 2020 EVENTS....Continue enrollment with IMGN632 monotherapy in relapsed AML, ALL, BPDCN, and MRD+ AML expansion cohorts and in combinations in AML; Present IMGN632 BPDCN and AML combination and MRD+ monotherapy data at ASH in December; File IND for IMGC936 in the first half of 2020; Transition next generation anti-folate receptor alpha (FRα) ADC, IMGN151, to pre-clinical development in mid-2020."

Clinical • Clinical data • Enrollment status • IND

ImmunoGen reports recent progress and third quarter 2019 financial results (Immunogen Press Release) - “ANTICIPATED UPCOMING EVENTS: Initiate MIRASOL by year-end; Present preclinical combination data (poster presentation) and updated clinical monotherapy data (oral presentation) for IMGN632 with additional patients enrolled in AML and BPDCN expansion cohorts at the American Society of Hematology (ASH) Annual Meeting in December; IND filing for IMGC936 in the first half of 2020; Present initial data from FORWARD II platinum agnostic and updated triplet combination studies in mid-2020; Transition next generation anti-FRα ADC, IMGN151, to pre-clinical development in mid-2020.”

IND • P1/2 data • Preclinical • Trial status